On 22 March 2023, the Geroscience Translational Research & International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force met in Toulouse, France to discuss avenues to foster the development of intrinsic capacity and frailty clinical trials under a geroscience perspective. A synthesis of these discussions and a set of recommendations are presented in this Meeting Report.
References
Cesari, M. et al. J. Gerontol. A Biol. Sci. Med. Sci. 73, 1653–1660 (2018).
Beard, J. R. et al. Lancet 387, 2145–2154 (2016).
Dent, E. et al. Lancet Lond Engl. 394, 1376–1386 (2019).
WHO. Integrated care for older people (ICOPE): guidance for person-centred assessment and pathways in primary care. who.int, https://www.who.int/publications/i/item/WHO-FWC-ALC-19.1 (2019)
Raffaele, M. & Vinciguerra, M. Lancet Healthy Longev. 3, e67–e77 (2022).
Vinel, C. et al. Nat. Med. 24, 1360–1371 (2018).
Cawthon, P. M. et al. J. Gerontol. A Biol. Sci. Med. Sci. 76, 123–130 (2021).
Roberts, M. N. et al. Cell Metab. 26, 539–546.e5 (2017).
Kim, D. H. et al. Aging 11, 1283–1304 (2019).
Ostan, R. et al. Clin. Nutr. 35, 812–818 (2016).
Lu, W. H. et al. J. Cachexia Sarcopenia Muscle 14, 930–939 (2023).
Andrieu, S. et al. Lancet Neurol. 16, 377–389 (2017).
Barzilai, N., Crandall, J. P., Kritchevsky, S. B. & Espeland, M. A. Cell Metab. 23, 1060–1065 (2016).
Tavassoli, N. et al. Lancet Healthy Longev. 3, e394–e404 (2022).
Santin, Y. et al. J. Frailty Aging 10, 121–131 (2021).
Acknowledgements
This task force was developed in the context of the Inspire program, a research platform that is supported by grants from the Region Occitanie/Pyrénées-Méditerranée (reference number 1901175) and the European Regional Development Fund (ERDF) (project number MP0022856). R.A.F. is partially supported by the US Department of Agriculture (USDA), under agreement no. 58-8050-9-004, by NIH Boston Claude D. Pepper Center (Older Americans Independence Centers; 1P30AG031679). Any opinions, findings, conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA. We thank all task force members: S. Andrieu (Toulouse, France), D. Angioni (Toulouse, France), M. Aubertin Leheudre (Montreal, Canada); N. Barcons (Esplugues de Llobregat, Barcelona, Spain), A. Baruch (South San Francisco, USA), M. Camprubi-Robles (Granada, Spain), M. Canevelli (Rome, Italy), M. Cesari (Milan, Italy), L. Chen (Richmond, USA), A. Cherubini (Ancona, Italy), R. Correa-de-Araujo (Bethesda, USA), P. D’Alessio (Evry, France), C. Delannoy (Vevey, Switzerland), W. Dioh (Paris, France), C. Dray (Toulouse, France), W. Evans (Durham, USA), R. Hughes (Richmond, USA), S. Hüttner (Heusden-Zolder, Belgium), J. Justice (Winston-Salem, USA), A. Khachaturian (Rockville, USA), S. Kritchevsky (Winston-Salem, USA), S. LaHue (San Francisco, USA), J. Mariani (Paris, France), M. McCormick (Albuquerque, USA), R. Merchant (Singapore, Singapore), A. Neale (Richmond, USA), J. Newman (Novato, USA), S. Pereira (Columbus, USA), E. Quann (Vevey, Switzerland), J. Yves Reginster (Clarens, Switzerland), L. Rodriguez Manas (Getafe, Spain), M. Rossulek (Cambridge, USA), S. Sourdet (Toulouse, France), B. Stubbs (Novato, USA), J. Touchon (Montpellier, France), C. Tourette (Paris, France) and J. Walston (Baltimore, USA).
Author information
Authors and Affiliations
Contributions
P.d.S.B. wrote the first draft of the manuscript. All authors revised the manuscript with important intellectual content. All authors had final responsibility for the decision to submit for publication
Corresponding author
Ethics declarations
Competing interests
P.d.S.B. declares consultancy fees from Pfizer. R.A.F. reports grants, personal fees and stock options from Axcella Health, other from Juvicell, other from Inside Tracker, grants and personal fees from Biophytis, personal fees from Amazentis, personal fees from Nestle, personal fees from Rejuvenate Biomed, personal fees from Pfizer and personal fees from Embion outside the submitted work. B.V. is an investigator in clinical trials at Toulouse University Hospital (IHU HealthAge, Inspire Geroscience Program). He has served as a scientific advisory board (SAB) member for Biogen, Alzheon, Green Valey, Norvo Nordisk and Longeveron, but received no personal compensation. He has served as consultant and/or SAB member for Roche, Lilly, Eisai and TauX with personal compensation. His family members have equity ownership interest in Serd publisher. He is member of the editorial board of the Journal of Prevention of Alzheimer’s Disease with no personal compensation. All of the remaining authors declare no competing interests.
Rights and permissions
About this article
Cite this article
de Souto Barreto, P., Rolland, Y., Ferrucci, L. et al. Looking at frailty and intrinsic capacity through a geroscience lens: the ICFSR & Geroscience Task Force. Nat Aging 3, 1474–1479 (2023). https://doi.org/10.1038/s43587-023-00531-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-023-00531-w
- Springer Nature America, Inc.
This article is cited by
-
Global Healthspan Summit 2023: closing the gap between healthspan and lifespan
Nature Aging (2024)